Norris Medicines reports standalone net loss of Rs 0.05 crore in the June 2021 quarter

Norris Medicines reports standalone net loss of Rs 3.17 crore in the March 2021 quarter

Price return has been average, nothing exciting

Seems to be overvalued vs the market average

Lagging behind the market in financials growth

Average profitability - not good, not bad

Good time to consider, stock is not in the overbought zone

The stock has a moderate number of red flags

Norris Medicines is engaged in business of pharmaceuticals.

With a market cap of ₹19 cr, stock is ranked 4,190